Innovations in Ukrainian medicine: priorities, directions, and forecasts

Abstract

Aims: There is a tangible informative lack in terms of medical innovation in Ukraine. Little accessible information regarding the steps being taken to foster medical innovation in Ukraine is due to the country's ongoing conflict and the significant pressure on its healthcare sector. Such an informative gap emphasises the necessity for additional research into Ukraine's unique medical landscape. Study design: Literature review Methodology: MEDLINE, Cochrane Reviews, and Pedro were among the databases used to conduct the literature search. The conjunctions "AND" and "OR" were used with certain keywords. The articles' time range was restricted between 2018 and 2022 in order to evaluate only present recent facts. Papers discussing innovative medicine, their development, distribution or procurement were included in the inclusion criteria. Results: Most studies examined how could be achieved the access to revolutionary medicine ignoring the medicine development. The creation of innovative medications was the subject of just one study. Most of the research discussed HTA and MEA and how important they were to ensuring patients had easy access to cutting-edge medications. Legislative or economic restrictions were the only one’s present. Conclusion: It is unclear how innovative pharmaceutical development is currently progressing in Ukraine. Health Technology Assessment (HTA) and Managed Entry Agreements (MEA) are being used to improve the access to innovative medicine in Ukraine. Buying medications for chronic illnesses is simple and convenient. In order to develop and distribute new medicine in Ukraine, regulatory and economic restrictions must be removed. Scientific Novelty: This study is the first to analyse the availability or development of innovative medication, therefore it can serve as the foundation for future studies by other groups. However, it would necessitate further on-the-ground research concerning the actual situation surrounding the creation, dissemination, and acquisition of innovative medicines. The ongoing war effort may hinder this.